Post hoc analysis of the Exenatide‐PD trial—Factors that predict response

Exenatide, a glucagon‐like peptide‐1 agonist and a licensed treatment for Type 2 diabetes significantly reduced deterioration in motor symptoms in patients with Parkinson's disease in a randomized, placebo‐controlled trial. In addition, there were trends favouring the exenatide group in assessm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European journal of neuroscience 2019-02, Vol.49 (3), p.410-421
Hauptverfasser:	Athauda, Dilan, Maclagan, Kate, Budnik, Natalia, Zampedri, Luca, Hibbert, Steve, Aviles‐Olmos, Iciar, Chowdhury, Kashfia, Skene, Simon S., Limousin, Patricia, Foltynie, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Body mass index clinical trial Clinical trials Cognition Cognition & reasoning Diabetes mellitus Diabetes mellitus (non-insulin dependent) exenatide Foltynie Parkinson's disease Glucagon glucagon‐like peptide‐1 agonist Insulin Movement disorders Neurodegenerative diseases Parkinson's disease Patients Peptides Phenotypes Quality of life Therapeutic applications Tremor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!